UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

~~Pursuant~~Date toof ~~Section 13~~report ~~or 15~~(d)Date of ~~the~~earliest ~~Securities~~event ~~Exchange~~reported) March 16, ~~Act of 1934~~2006

~~Date~~Andrx ~~of Report (Date of Earliest Event Reported): December 14, 2005~~Corporation

~~Andrx Corporation __________________________________________~~ (Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its~~Its ~~charter~~Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

Delaware	0-31475	65-1013859
0-31475		65-1013859
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
(Commission File Number)		(IRS Employer Identification No.)
of incorporation)	File Number)	Identification No.)
4955 Orange Drive, Davie, Florida		33314
_________________________________ (Address of principal executive offices)		___________ (Zip Code)
(Address of Principal Executive Offices)		(Zip Code)

~~Registrant’s telephone number, including area code:~~ 954-584-0300

~~Not~~(Registrant’s ~~Applicable ______________________________________________ Former~~Telephone ~~name or former address~~Number, ifIncluding ~~changed~~Area ~~since last report~~ Code)

~~Check~~(Former ~~the~~Name ~~appropriate~~or ~~box~~Former ~~below~~Address, if ~~the~~Changed ~~Form~~Since ~~8-K~~Last ~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~ Report)

~~[ ] Written~~ Check ~~communications~~the ~~pursuant~~appropriate tobox ~~Rule~~below ~~425~~if ~~under~~ the ~~Securities~~Form ~~Act~~8-K ~~(17~~filing ~~CFR~~is ~~230.425) [ ] Soliciting~~intended ~~material pursuant~~ to ~~Rule~~simultaneously satisfy ~~14a-12 under~~ the ~~Exchange~~filing ~~Act~~obligation ~~(17~~of ~~CFR~~the ~~240.14a-12) [ ] Pre-commencement~~registrant ~~communications~~under ~~pursuant~~any toof ~~Rule 14d-2(b) under~~ the ~~Exchange~~following ~~Act~~provisions (17see ~~CFR~~General Instruction ~~240~~A.~~14d-~~2~~(b)) [ ] Pre-commencement~~. ~~communications pursuant to Rule 13e-4(c~~below) ~~under the Exchange Act (17 CFR 240.13e-4(c))~~:

~~Top~~ o ofWritten communications pursuant to Rule 425 under the ~~Form~~Securities Act (17 CFR 230.425)

~~Item~~ x ~~8.01~~Soliciting ~~Other~~material ~~Events~~pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

On o ~~December~~Pre-commencement ~~14,~~communications ~~2005,~~pursuant ~~Andrx Corporation ("Andrx" or the "Company") met with the Food and Drug Administration (FDA)~~ to present its responses to the FDA’s Form 483 – List of Observations of May 2005, as well as the actions taken by the Company to maintain and improve its manufacturing and quality operations. As the Company anticipated, the FDA will be conducting an inspection to evaluate the Company’s actions. The FDA did not comment on the timing of such inspection.ForwardRule 14d-~~looking statements~~ 2(~~statements which are not historical facts~~b) inunder ~~this report are made pursuant to~~ the ~~safe~~Exchange ~~harbor provisions of the Private Securities Litigation Reform~~ Act of(17 CFR ~~1995~~240. ~~For this purpose, any statements contained herein or which are otherwise made by or on behalf of Andrx that are not statements of historical fact may be deemed to be forward~~14d-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the FDA’s pending inspection; what sanctions, if any, FDA may seek following its decision to place us in OAI 2(~~Official Action Indicated~~b) status, including without limitation sanctions relating to any failure to comply with cGMP requirements and if and when the "hold" on our ANDA approvals will be lifted; government regulation generally; competition; manufacturing capacities, safety issues, output and quality processes; our inability to obtain sufficient supplies and/or active pharmaceuticals from key suppliers; recent management changes and the potential loss of senior management and other key personnel; the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. Actual results may differ materially from those projected in a forward-looking statement. We are also subject to other risks detailed herein or detailed from time to time in our 2004 10-K or in our other SEC filings. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our 2004 10-K and in our other SEC filings.)

~~Top~~ o ofPre-commencement communications pursuant to Rule 13e-4(c) under the ~~Form~~Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On March 16, 2006, Andrx Corporation announced its earnings for the three months and year ended December 31, 2005. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such results.

Item 8.01 See press release dated March 16, 2006 attached hereto as Exhibit 99.1

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Additional Information and Where to Find It

Andrx has filed a Form 8-K with the SEC regarding the proposed merger with Watson, which includes a copy of the definitive merger agreement. All parties desiring details regarding the conditions of this transaction are urged to review the contents of the definitive agreement, which is available at the SEC’s website at http://www.sec.gov/.

This filing may be deemed to be solicitation material in respect of the proposed merger of Watson and Andrx. In connection with the proposed merger, Andrx will file a proxy statement with the SEC. INVESTORS AND SECURITY HOLDERS OF ANDRX ARE ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. The final proxy statement will be mailed to stockholders of Andrx. Investors and security holders may obtain a free copy of the proxy statement, when it becomes available, and other documents filed by Andrx with the SEC, at the SEC’s web site at http://www.sec.gov. Free copies of the proxy statement, when it becomes available, and the company’s other filings with the SEC may also be obtained from the company. Free copies of Andrx’s filings may be obtained by directing a request to Andrx Corporation, 4955 Orange Drive, Davie, Florida 33314, Attention: Investor Relations.

Participants in Solicitation

Andrx, Watson and their respective directors, executive officers and other members of their management and employees may be deemed to be soliciting proxies from their respective stockholders in favor of the merger. Information regarding Watson’s directors and executive officers is available in Watson’s proxy statement for its 2005 annual meeting of stockholders, which was filed with the SEC on April 1, 2005. Information regarding Andrx’s directors and executive officers is available in Andrx’s proxy statement for its 2005 annual meeting of stockholders, while was filed with the SEC on April 19, 2005. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the ~~registrant~~ Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Andrx Corporation
	ANDRX CORPORATION
December 15, 2005		By:	/s/ Robert I. Goldfarb
Date: March 17, 2006	By:	/s/ Angelo C. Malahias
			Name: Robert I. Goldfarb
		Angelo C. Malahias
			Title: Senior Vice President, General Counsel and Secretary
		President

Filing Compare · ANDRX CORP /DE/